
Important hurdle overcome for the drug for weight control and type 2 diabetes
AI-generated summary
Eli Lilly has received a recommendation from the EMA to approve the weight loss pill Foundayo.
Berlin. The US pharmaceutical company Eli Lilly has overcome an important hurdle on the way to approval in the European Union for its weight loss pill Foundayo. A committee of the EU Medicines Agency (EMA) recommended approval of the drug for weight control and the treatment of type 2 diabetes in adults on Friday.
The EU Commission must now agree to the recommendation before Eli Lilly can bring the product onto the market. Foundayo would be the second oral drug of its kind to be approved in the EU, after Danish rival Novo Nordisk's Wegovy pill.
AI outlook — possibilities, not facts
EU Commission approves the approval
Likely · Within months

Due to the impending shortage of general practitioners in Germany and Brandenburg, the Medical University of Lausitz has started operations in Cottbus with its first students. A new country doctor quota should provide long-term relief.

In the Malteser practice in Stuttgart, more and more people without health insurance are seeking medical help. In addition to refugees and homeless people, pensioners and self-employed people who fell out of the system due to contribution debts are increasingly affected.
A study published in the journal Nature Medicine describes menopause as a “physiological cliff.” Researchers evaluated 300 million laboratory data and found that metabolism, organ functions and hormones were already changing abruptly years before.

Former Olympic sprinter Beth Dobbin suffers from the chronic multisystem disease ME/CFS. She reports on the severity of the symptoms, the lack of recognition of the disease and the lack of effective treatment options.

Health economist Boris Augurzky criticizes the contribution rate stabilization law as a short-term shift in burdens to the detriment of hospitals and calls for structural reforms, reductions in bureaucracy and a sensible approach to the sugar tax.

The CEO of the National Association of Statutory Health Insurance Funds, Oliver Blatt, calls for a fairer allocation of doctor's appointments based on medical needs instead of insurance status. He criticizes the current disadvantage of the 75 million people with statutory health insurance as 'blazing injustice' and rejects the term two-class medicine, while proposing a daily platform for making appointments.